Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Transparency of R&D Costs Also Requested

Executive Summary

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

You may also be interested in...



Pharma Snubs WHO Call To Pool COVID-19 Patents

Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’

Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe

A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.

Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe

A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel